PAR-2-mediated control of barrier function and motility differs between early and late phases of postinfectious gut dysfunction in the rat

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 4, 2013, Pages

  Fernández Blanco, Juan A ^a   Hollenberg, Morley D ^c   Martínez, Vicente ^a,b,d   Vergara, Patri ^a,b,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c UNIVERSITY OF CALGARY   (Canada)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Functional gastrointestinal disorders; Irritable bowel syndrome; Ketotifen; Mast cell; Proteinase activated receptors

Indexed keywords

KETOTIFEN; PROTEINASE ACTIVATED RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTERITIS; ENTEROPATHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE MOTILITY; ION TRANSPORT; MALE; MAST CELL; NONHUMAN; POSTINFECTIOUS GUT DYSFUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRICHINELLA SPIRALIS; TRICHINOSIS;

ANIMALS; GASTROENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; KETOTIFEN; MALE; MAST CELLS; MUSCLE CONTRACTION; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; TRICHINELLA SPIRALIS; TRICHINELLOSIS;

EID: 84874056757     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00387.2012     Document Type: Article

References (47)

1. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130: 248-282, 2011.
2. Al-Ani B, Saifeddine M, Kawabata A, Renaux B, Mokashi S, Hollenberg MD. Proteinase-activated receptor 2 (PAR2): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)-and PAR(2)-derived peptide ligands. J Pharmacol Exp Ther 290: 753-760, 1999.
3. Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 16: 2978-2990, 2010.
4. Castro GA, Fairbairn D. Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro. J Parasitol 55: 51-58, 1969.
5. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117: 636-647, 2007.
6. Compton SJ, McGuire JJ, Saifeddine M, Hollenberg MD. Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta. Can J Physiol Pharmacol 80: 987-992, 2002.
7. De Giorgio R, Barbara G, Blennerhassett P, Wang L, Stanghellini V, Corinaldesi R, Collins SM, Tougas G. Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in the nematode infected rat. Gut 49: 822-827, 2001.
8. de Jonge WJ, The FO, van der Coelen D, Bennink RJ, Reitsma PH, van Deventer SJ, van den Wijngaard RM, Boeckxstaens GE. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology 127: 535-545, 2004.
9. Devlin MG, Gasser RB, Cocks TM. Initial support for the hypothesis that PAR2 is involved in the immune response to Nippostrongylus brasiliensis in mice. Parasitol Res 101: 105-109, 2007.
10. Fernandez-Blanco JA, Barbosa S, Sanchez de Medina F, Martinez V, Vergara P. Persistent epithelial barrier alterations in a rat model of postinfectious gut dysfunction. Neurogastroenterol Motil 23: e523-e533, 2011.
11. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56: 203-209, 2007.
12. Gunther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. In press. DOI:10.1136/gutjnl-2011-301364.
13. Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A, Wallace JL, Hollenberg MD, Vergnolle N. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci USA 102: 8363-8368, 2005.
14. Juanola C, Giralt M, Jimenez M, Mourelle M, Vergara P. Mucosal mast cells are involved in CCK disruption of MMC in the rat intestine. Am J Physiol Gastrointest Liver Physiol 275: G63-G67, 1998.
15. Kawabata A, Kuroda R, Nagata N, Kawao N, Masuko T, Nishikawa H, Kawai K. In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. Br J Pharmacol 133: 1213-1218, 2001.
16. Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 20: 900-907, 2008.
17. Khan WI, Collins SM. Immune-mediated alteration in gut physiology and its role in host defence in nematode infection. Parasite Immunol 26: 319-326, 2004.
18. Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, Yeom JJ, Kim TH, Nah YH, Lee YM. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 9: 224-229, 2003.
19. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59: 1213-1221, 2010.
20. Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skaregarde A, Gedda K, Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW. Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem 282: 26089-26100, 2007.
21. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Bohm SK, Bunnett NW. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 94: 8884-8889, 1997.
22. Lee JW, Park JH, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci 55: 2922-2928, 2010.
23. Martinez-Augustin O, Romero-Calvo I, Suarez MD, Zarzuelo A, de Medina FS. Molecular bases of impaired water and ion movements in inflammatory bowel diseases. Inflamm Bowel Dis 15: 114-127, 2009.
24. McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grencis RK. Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl Acad Sci USA 100: 7761-7766, 2003.
25. Mule F, Baffi MC, Capparelli A, Pizzuti R. Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle. Br J Pharmacol 139: 598-604, 2003.
26. Mule F, Baffi MC, Cerra MC. Dual effect mediated by proteaseactivated receptors on the mechanical activity of rat colon. Br J Pharmacol 136: 367-374, 2002.
27. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040-6049, 2004.
28. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol 95: 167-255, 2007.
29. Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, Bunnett NW, Vanner SJ. Mast cell tryptase and proteinaseactivated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. J Physiol 547: 531-542, 2003.
30. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 116: 207-235, 2007.
31. Roka R, Ait-Belgnaoui A, Salvador-Cartier C, Garcia-Villar R, Fioramonti J, Eutamene H, Bueno L. Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats. Gut 56: 1072-1078, 2007.
32. Roka R, Demaude J, Cenac N, Ferrier L, Salvador-Cartier C, Garcia-Villar R, Fioramonti J, Bueno L. Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice. Neurogastroenterol Motil 19: 57-65, 2007.
33. Roka R, Wittmann T, Bueno L. Altered protease signalling in the gut: a novel pathophysiological factor in irritable bowel syndrome. Neurogastroenterol Motil 20: 853-856, 2008.
34. Schepens MA, Rijnierse A, Schonewille AJ, Vink C, Brummer RJ, Willemsen LE, van der Meer R, Bovee-Oudenhoven IM. Dietary calcium decreases but short-chain fructo-oligosaccharides increase colonic permeability in rats. Br J Nutr 104: 1780-1786, 2010.
35. Serna H, Porras M, Vergara P. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther 319: 1104-1111, 2006.
36. Shea-Donohue T, Notari L, Stiltz J, Sun R, Madden KB, Urban JF Jr, Zhao A. Role of enteric nerves in immune-mediated changes in proteaseactivated receptor 2 effects on gut function. Neurogastroenterol Motil 22: 1138-e291, 2010.
37. Stewart GL, Na H, Smart L, Seelig LL Jr. The temporal relationship among anti-parasite immune elements expressed during the early phase of infection of the rat with Trichinella spiralis. Parasitol Res 85: 672-677, 1999.
38. Stoyanova II, Gulubova MV. Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochem 104: 185-192, 2002.
39. Swystun VA, Renaux B, Moreau F, Wen S, Peplowski MA, Hollenberg MD, MacNaughton WK. Serine proteases decrease intestinal epithelial ion permeability by activation of protein kinase Czeta. Am J Physiol Gastrointest Liver Physiol 297: G60-G70, 2009.
40. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Takahama K, Watanabe M, Nakano H, Hirata I, Arisawa T. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med 9: 125-130, 2009.
41. Tanovic A, Jimenez M, Fernandez E. Changes in the inhibitory responses to electrical field stimulation of intestinal smooth muscle from Trichinella spiralis infected rats. Life Sci 71: 3121-3136, 2002.
42. The FO, Buist MR, Lei A, Bennink RJ, Hofland J, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol 104: 2257-2266, 2009.
43. Torrents D, Vergara P. In vivo changes in the intestinal reflexes and the response to CCK in the inflamed small intestine of the rat. Am J Physiol Gastrointest Liver Physiol 279: G543-G551, 2000.
44. Trap C, Fu B, Le Guerhier F, Liu M, Le Rhun D, Romand T, Perret C, Blaga R, Boireau P. Cloning and analysis of a cDNA encoding a putative serine protease comprising two trypsin-like domains of Trichinella spiralis. Parasitol Res 98: 288-294, 2006.
45. Traver E, Torres R, de Mora F, Vergara P. Mucosal mast cells mediate motor response induced by chronic oral exposure to ovalbumin in the rat gastrointestinal tract. Neurogastroenterol Motil 22: e34-e43, 2010.
46. Tremaine WJ, Brzezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, Strenkoski-Nix LC, Kurth MC, AXYS Ulcerative Colitis Study Group. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther 16: 407-413, 2002.
47. Vergnolle N, Macnaughton WK, Al-Ani B, Saifeddine M, Wallace JL, Hollenberg MD. Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci USA 95: 766-7771, 1998.